Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
about
RAGE: a new frontier in chronic airways diseaseUnderstanding the substrate specificity of the heparan sulfate sulfotransferases by an integrated biosynthetic and crystallographic approachHeparan sulfate signaling in cancerNovel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosaceaPrevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycanDisruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritisHigh-Mobility Group Box 1 Disrupts Metabolic Function with Cigarette Smoke Exposure in a Ceramide-Dependent Manner.2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.The effect of a polyurethane coating incorporating both a thrombin inhibitor and nitric oxide on hemocompatibility in extracorporeal circulationEffect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study.Longistatin in tick saliva blocks advanced glycation end-product receptor activation.Mitochondrial transcription factor A, an endogenous danger signal, promotes TNFα release via RAGE- and TLR9-responsive plasmacytoid dendritic cells.Inhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence.Interactions between coagulation and complement--their role in inflammationHeparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria.A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharidesThe multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Targeted therapies for bone sarcomas.2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity.Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells.Up-Regulation of Claudin-6 in the Distal Lung Impacts Secondhand Smoke-Induced InflammationHeparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease.Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells.Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling.Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice.Bone sarcomas: from biology to targeted therapies.Conditionally induced RAGE expression by proximal airway epithelial cells in transgenic mice causes lung inflammation.Hyperoxia, HMGB1, and ventilator-associated pneumonia: reducing risk by practicing what we teach.Effects of subcutaneous low molecular weight heparin and intravenous unfractionated heparin on serum S100 concentrations in patients with cerebrovascular diseases.Ousting RAGE in melanoma: A viable therapeutic target?Conditional overexpression of receptors for advanced glycation end-products in the adult murine lung causes airspace enlargement and induces inflammation.
P2860
Q27025295-64FE0D34-B6B7-4C47-BDF7-62FF31B30B7CQ27028136-1EABA66C-4E31-4187-B170-59E137E636D3Q28657828-727400A7-4B83-4B02-AB33-0686E103CD0FQ28742923-519D99EE-D67B-4349-8E52-9C68353B8E5FQ31143378-F29FE436-6309-4D79-A951-904FFED2AF5AQ33399613-DB36E10E-A512-446B-905E-EEC18D514D17Q33406904-3058F7FD-AC03-4D9D-AAEF-85138575D870Q33410310-C6ECEA5B-E6AA-4B15-B787-19D63C616DB0Q33416269-24497DFB-9F61-412C-95E1-7F9466DC3524Q33574588-6975FC03-18BB-4581-9F29-B4EFD7198ACBQ33755472-1CA1FD24-3272-4F1F-96E6-E86AF45B6B95Q33799602-E7B76B41-D348-4DD6-A4A9-BB2DDBED28BBQ33808326-6027821A-0D35-4E95-97CF-80707F58D045Q33904369-4594F034-CABF-4907-A04E-6066906512BEQ34158016-5DCD6978-F877-4F3B-BB4A-5E432D87E14DQ34311706-26016EF5-567E-4EF5-BF7C-FC542674CBBBQ34951563-06BF5343-1B39-4A96-A556-6ECEC1AA6C2CQ35812192-8A12B581-5258-4126-9A85-6BF097604991Q36022738-550CF399-2E1A-47F0-889E-E1724C16BB61Q36025124-8833B6FD-7EC1-4654-8FE0-72B13D17588AQ36743870-189157B2-9E1A-4D7E-A2CF-6156DA4854EFQ37458645-1AAD3F81-23EE-498D-8A82-5692C00E6DDDQ37808230-B523E6EE-97FC-4934-9EA8-EB63F0281208Q38077593-A3CA0C5D-9230-4ED1-B6F7-0492654D5D38Q38096444-7AD5E465-7886-46AD-85F9-A1A0BA2D0AE6Q38178277-DB2E0929-53D2-41FE-94F9-189A204F2326Q38748673-3C7541A7-81F0-4212-907D-E9081F31C3B7Q39192067-5D11C71A-11A5-488A-9345-E4BB325EA619Q39267369-B696C2E5-3F2F-4D4D-AE03-32EDB899151DQ39281099-BC095778-922D-4334-A376-A60B9EB35877Q39366052-FC424D24-DD36-4840-BB20-65655963863EQ39683706-F8FD887B-79E4-436B-A4AF-A26EA8F49692Q41036883-0A011AE8-5127-4C5C-B9E9-52D2F8F18F70Q41880812-34E3611D-352B-4D7C-B9EF-4BF2F613EEE8Q41923624-86D8477D-8B40-41C4-A220-E329721B0E89Q42106315-349E4296-1BC0-41C0-A790-A0C868B182A6Q42554510-E2DBCF6A-1FFF-4FAE-A1FD-8F77C560077DQ47315672-D0B9417F-7358-449C-91EE-8A4137CDD17FQ47593410-0463AB55-764C-428A-8E25-040DC0B90AD1Q50752074-24FAD6E1-8310-4FD9-8652-49DCD875777C
P2860
Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@ast
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@en
type
label
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@ast
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@en
prefLabel
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@ast
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@en
P2093
P2860
P921
P1476
Low anticoagulant heparin targ ...... tion of RAGE with its ligands.
@en
P2093
Bradford B Walters
Brian Argyle
Glenn D Prestwich
Jeanine M Walenga
John R Hoidal
Margaret Prechel
Narayanam V Rao
Robert B MacArthur
Thomas P Kennedy
P2860
P304
P356
10.1152/AJPCELL.00009.2010
P577
2010-04-07T00:00:00Z